

Laura A Adang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6441079/publications.pdf>

Version: 2024-02-01

36
papers

725
citations

566801

15
h-index

610482

24
g-index

38
all docs

38
docs citations

38
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 601-613.	0.5	31
2	Clinical, neuroradiological, and molecular characterization of patients with atypical Zellweger spectrum disorder caused by PEX16 mutations: a case series. <i>Neurogenetics</i> , 2022, 23, 115-127.	0.7	0
3	Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi). <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 48.	1.2	10
4	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <sc>CANDLE</sc>/<sc>PRAAS</sc>, <sc>SAVI</sc>, and <sc>AGS</sc>. <i>Arthritis and Rheumatology</i> , 2022, 74, 735-751.	2.9	23
5	Newborn Screening for X-Linked Adrenoleukodystrophy: Review of Data and Outcomes in Pennsylvania. <i>International Journal of Neonatal Screening</i> , 2022, 8, 24.	1.2	11
6	Early developmental delay in Leigh syndrome spectrum disorders is associated with poor clinical prognosis. <i>Molecular Genetics and Metabolism</i> , 2022, 135, 342-349.	0.5	2
7	Hematologic abnormalities in Aicardi GoutiÃres Syndrome. <i>Molecular Genetics and Metabolism</i> , 2022, 136, 324-329.	0.5	8
8	Late-Onset Aicardi-GoutiÃres Syndrome: A Characterization of Presenting Clinical Features. <i>Pediatric Neurology</i> , 2021, 115, 1-6.	1.0	18
9	Hepatic Involvement in Aicardi-GoutiÃres Syndrome. <i>Neuropediatrics</i> , 2021, 52, 441-447.	0.3	6
10	<sc>MRI</sc> surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 728-739.	1.7	39
11	Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 1700-1711.	0.7	16
12	Widening the MRI Findings of PLA2G6-Associated Neurodegeneration. <i>Neuropediatrics</i> , 2021, 52, 509-510.	0.3	0
13	Consensus clinical management guideline for beta-propeller protein-associated neurodegeneration. <i>Developmental Medicine and Child Neurology</i> , 2021, 63, 1402-1409.	1.1	17
14	Reliability of the Telemedicine Application of the Gross Motor Function Measure-88 in Patients With Leukodystrophy. <i>Pediatric Neurology</i> , 2021, 125, 34-39.	1.0	6
15	Improved Gene Therapy for Metachromatic Leukodystrophy. <i>Blood</i> , 2021, 138, 3979-3979.	0.6	0
16	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. <i>Frontiers in Public Health</i> , 2021, 9, 751451.	1.3	9
17	Developmental Outcomes of Aicardi GoutiÃres Syndrome. <i>Journal of Child Neurology</i> , 2020, 35, 7-16.	0.7	40
18	Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. <i>Human Mutation</i> , 2020, 41, 837-849.	1.1	63

#	ARTICLE	IF	CITATIONS
19	Glial cells in the driver seat of leukodystrophy pathogenesis. <i>Neurobiology of Disease</i> , 2020, 146, 105087.	2.1	16
20	Natural history of multiple sulfatase deficiency: Retrospective phenotyping and functional variant analysis to characterize an ultra-rare disease. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1298-1309.	1.7	23
21	Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. <i>New England Journal of Medicine</i> , 2020, 383, 986-989.	13.9	109
22	Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3448.	1.8	32
23	Phenotypic and Imaging Spectrum Associated With WDR45. <i>Pediatric Neurology</i> , 2020, 109, 56-62.	1.0	16
24	A systematic review and meta-analysis of published cases reveals the natural disease history in multiple sulfatase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1288-1297.	1.7	14
25	Leukocyte and Dried Blood Spot Arylsulfatase A Assay by Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2020, 92, 6341-6348.	3.2	17
26	Development of a neurologic severity scale for Aicardi Goutières Syndrome. <i>Molecular Genetics and Metabolism</i> , 2020, 130, 153-160.	0.5	25
27	Validation of a symptom-based questionnaire for pediatric CNS demyelinating diseases. <i>Journal of AAPOS</i> , 2019, 23, 157.e1-157.e7.	0.2	3
28	Neuropathological Findings in a Case of <i>IFIH1</i> -Related Aicardi-Goutières Syndrome. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 566-570.	0.5	7
29	Teaching NeuroImages: Cranial neuropathies following clival infarction. <i>Neurology</i> , 2019, 93, e1031.	1.5	0
30	Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement. <i>Molecular Genetics and Metabolism</i> , 2018, 123, 337-346.	0.5	31
31	Teaching NeuroImages: Atrophy in epileptic encephalopathy. <i>Neurology</i> , 2018, 90, e442-e443.	1.5	1
32	Mutations in <i>SZT2</i> result in early-onset epileptic encephalopathy and leukoencephalopathy. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 1443-1448.	0.7	15
33	Aicardi goutières syndrome is associated with pulmonary hypertension. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 351-358.	0.5	35
34	Pediatric Multiple Sclerosis. <i>Current Pediatrics Reports</i> , 2017, 5, 6-12.	1.7	0
35	Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 18-32.	0.5	42
36	Progressive Multifocal Leukoencephalopathy. <i>F1000Research</i> , 2015, 4, 1424.	0.8	39